Optical Coherence Tomography Angiography (OCT-A) and Non-invasive Dynamic Vessel Analysis (DVA)

Project description

Optical coherence tomography angiography (OCT-A) and dynamic fundus vascular analysis (DVA) studies, as part of the diagnostic platform within the National Clinical Study Group (NKSG).

The aim of the NKSG diagnostic platform is to identify diagnostic and prognostic markers of post-COVID syndrome (PCS) and ME/CFS in order to investigate treatment effects on imaging and vascular markers. The results of the diagnostic platform will improve the understanding of the disease and identify possible new treatment options. In addition to the therapeutic interventions in the respective NKSG clinical trials, patients part-taking in the NKSG hence receive state-of-the-art accompanying examinations. These include non-invasive analyses of the structure, function and blood flow of the brain via magnetic resonance imaging (MRI) and accompanying ASL, examinations of vascular endothelial function using Endothelial Peripheral Arterial Tonometry (EndoPAT) and DVA, as well as measurement of retinal microcirculation using OCT-A. The examinations take place before and after treatment interventions and thus enable the effect of specific treatments to be analysed in-depth. In addition to study-specific clinical parameters, objective measurements of brain structure and function, vascular endothelial function and retinal microcirculation are available. These data enable an additional assessment of the effectiveness and mechanisms of action as well as a comparison of the different therapeutic approaches.

The diagnostic platform also takes current research results into account: PCS is associated with reduced cognitive performance and fatigue, is accompanied by structural and functional changes in the brain and can lead to disorders the retinal and choroidal microcirculation. The results of the NKSG diagnostic platform can therefore help to establish standards for data collection for MRI (incl ASL), OCT-A, DVA and EndoPAT, which will facilitate the future diagnosis of PCS and ME/CFS patients in everyday clinical practice and which may be used as endpoints in clinical trials.

(Description adapted from project website: see link above)